State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer

State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer Susan Goodin, Kamakshi V. Rao, Robert S. DiPaola Oncologist 2002; 7: 360-370 Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in genitourinary cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify agents that have shown activity in the treatment of hormone refractory prostate cancer (HRPC). Recognize the mechanisms of resistance to chemotherapy in HRPC, including genetic alterations commonly found in advanced disease. Recognize the development of novel approaches to the treatment of HRPC. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 16, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Aug. 16, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.